NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
85 trialsNCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT04393298 2025-05-29
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
Phase 1/2 Completed
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02826486 2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2 Completed
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT03414983 2023-11-18
CheckMate 9X8
Bristol-Myers Squibb
Phase 2/3 Completed
NCT02024607 2023-11-15
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT03750786 2023-10-26
AGENT
Isofol Medical AB
Phase 3 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed
NCT03504423 2023-01-03
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals
Phase 3 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT02551991 2022-10-10
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Ipsen
Phase 2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT01896531 2022-03-02
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Genentech, Inc.
Phase 2 Completed
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT03288987 2021-01-22
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
AryoGen Pharmed Co.
Phase 3 Completed
NCT02923921 2020-10-19
Sequoia
Eli Lilly and Company
Phase 3 Completed
NCT01681472 2020-09-25
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT00612586 2020-07-21
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT02545504 2020-05-26
GAMMA-1
Gilead Sciences
Phase 3 Completed
NCT00967616 2020-05-04
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
Phase 2 Completed
NCT02141295 2020-03-25
McCAVE
Hoffmann-La Roche
Phase 2 Terminated
NCT00069121 2020-03-06
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01228734 2020-01-28
TAILOR
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT01183780 2019-09-25
A Study in Second Line Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 3 Completed
NCT01479465 2019-04-17
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Gilead Sciences
Phase 2 Terminated
NCT01634555 2019-02-26
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Phase 2 Completed
NCT00252564 2019-02-15
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
US Oncology Research
Phase 3 Completed